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IMPLICATIONS OF GENOMICS ADVANCES FOR DRUG DISCOVERY, CLINICAL 
THERAPIES, & RARE DISEASE RESEARCH 
JOHN R. RAYMOND, MD 
PRESIDENT & CEO AND PROFESSOR OF MEDICINE 
MEDICAL COLLEGE OF WISCONSIN 
 
The burgeoning field of genomics offers immense promise for the 
transformational power of personalized medicine.  Genomics is the study of the 
full complement of DNA in an individual cell or organism.  Personalized 
medicine is the customization of health care therapies to the individual patient.  
By sequencing the genome (DNA) of an individual, one can unlock the secrets 
of genetic causes of rare diseases, customize therapies for specific cancer types, 
and identify predispositions for complex diseases.9  The ability to sequence the 
entirety of an individual’s genome, and to analyze and annotate it have 
improved exponentially over the last few years, to the point that it is 
conceivable, and perhaps inevitable, that anyone who wants to have their 
genome sequenced will be able to do so for a relatively nominal fee within the 
next few years.  The confluence of rapid, high-capacity sequencing 
instruments; new bioinformatic tools; a rapidly growing catalogue of disease 
mutations and allelic variations; and powerful computational resources and data 
storage availability will enable disruptive innovation that will make genomics 
an integral part of health care and wellness strategies in our lifetimes.  The 
transformative potential of genomics in personalized medicine is particularly 
meaningful to us in Milwaukee, as much of the groundbreaking work has been 
performed at and with the support of the Medical College of Wisconsin and 
Children’s Hospital of Wisconsin. 
 
9. Howard J. Jacob, et al., Genomics in Clinical Practice: Lessons from the Front Lines, 
5(194) SCIENCE TRANSLATIONAL MEDICINE 194cm5 (2013). 
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Genomics will revolutionize drug discovery in at least four ways.  First, by 
identifying the causes of rare diseases, scientists and clinicians will create clues 
about heretofore unknown and possibly unsuspected functions of genes.  These 
clues will lead to new mechanistic insights that will create novel “druggable” 
targets.  The druggable targets should be amenable to high throughput 
screening, in silico analyses and other drug discovery methodologies, which in 
turn, will lead to innovative therapies. 
Second, clinicians will be able to optimize drug therapy for specific 
syndromes for each patient based on their genomic sequences, by choosing the 
drugs that are most likely to work, and by avoiding those that can cause serious 
side effects.  It is now well known that a significant percentage of the 
population does not obtain a therapeutic benefit from clopidogrel,10 a potent 
(and expensive) anti-platelet agent used in the prevention of heart attacks and 
strokes.  Clopidogrel is a pro-drug that requires a certain enzyme (CYP2C19) 
to become active.  Genetic mutations of that enzyme impair the metabolism of 
clopidogrel, rendering it ineffective.  With regard to side effects, angiotensin-
converting enzyme inhibitors (ACEI) are highly effective antihypertensive 
drugs.  But, ACEI can cause a dry cough in a significant number of patients that 
can lead to non-compliance; ACEI also can cause life-threatening angioedema.  
Both of these side effects have been linked to or are suspected to be associated 
with specific genetic variations. 
Third, by knowing genetic predispositions of each patient for various 
“preventable” diseases, the patient could modify risk factors and behaviors 
(diet, smoking, exercise).  Those risk factors could be ameliorated directly by 
drug therapies, or perhaps indirectly with the assistance of new types of 
medicines or nutraceuticals that would encourage or enhance the effects of 
healthy behaviors.  Those medicines and nutraceuticals would be amenable to 
drug discovery. 
Fourth, a better understanding of the genetic bases of unwanted side effects 
of drugs could lead to improved agents with intact therapeutic profiles and 




10. Simon Tabassome, et al., Genetic determinants of response to clopidogrel and 
cardiovascular events, 360(4) N. ENGL. J. MED. 363–75 (2009). 
